Andres Yarur, MD
Gastroenterology · Los Angeles, CANPI 1558519256
Payments from drug & device makers
Across 358 payments — averaging $2522.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$316K
- Takeda Pharmaceuticals U.S.A., Inc.$298K
- AbbVie$65K
- Takeda$54K
- Genentech, Inc.$48K
- E.r. Squibb & Sons, L.L.C.$35K
- plus $86K from 10 others
Across 89 payments — averaging $1243.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$81K
- Takeda Pharmaceuticals U.S.A., Inc.$18K
- F. Hoffmann-la Roche AG$12K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 126 | $316,189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 75 | $297,760 |
| AbbVie | 17 | $65,440 |
| Takeda | 2 | $53,659 |
| Genentech, Inc. | 6 | $48,219 |
| E.r. Squibb & Sons, L.L.C. | 21 | $35,497 |
| Pfizer(2 entities) | 49 | $25,156 |
| Janssen Scientific Affairs, LLC | 10 | $10,079 |
| Merck | 10 | $8,612 |
| Janssen Global Services, LLC | 11 | $8,556 |
| Eli Lilly | 4 | $7,361 |
| Boehringer Ingelheim | 2 | $6,780 |
| Celltrion USA Inc. | 9 | $6,602 |
| Sanofi | 6 | $6,501 |
| Bristol Myers Squibb | 9 | $5,822 |
| Celltrion, Inc. | 1 | $675 |
How this compares
$902,908 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Los Angeles
- Gil MelmedLos Angeles$3M
- Bennett RothLos Angeles$2.8M
- Sammy SaabLos Angeles$2M
- Caroline HwangLos Angeles$908K
- Brennan SpiegelLos Angeles$845K
- Nicholas KaryotakisLos Angeles$710K
- Venkataraman MuthusamyLos Angeles$693K
- Sadeea AbbasiLos Angeles$556K
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.